People

Delos Capital partner since 2024, after serving as senior adviser and operating partner. Previously held scientific leadership roles at Moderna, including New Venture Labs and Moderna Genomics. Also serves on the boards of STRM.BIO and TRexBio, with the latter resignation planned before IPO registration effectiveness; based in Cambridge.

Delos Capital partner and founding team member, with experience in life sciences investment banking and venture investing. Serves on portfolio-company boards including STRM.BIO, Eccogene and Zenas; previously worked at Goldman Sachs. Based in Hong Kong.

Pfizer Ventures partner and business-development executive with a background in pharmaceutical chemistry and research. TRexBio director since January 2026, with resignation planned before IPO registration effectiveness. PfizerVentures primarypublished affiliation: Vice President, WWBD / Partner. Christopher O’Donnell, PhD is a Partner at Pfizer Ventures and Vice President, Worldwide Business Development. Chris is responsible for identifying, evaluating, making, and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Arrakis Therapeutics, Cartography Biosciences, Circle Pharma, Enlaza Therapeutics, Incendia Therapeutics, Kestrel Therapeutics, MindImmune, Nimbus, Pyxis Oncology (PYXS), Storm Therapeutics, Strata Oncology, TRex Bio, and Triana Biomedicines. He is also responsible for managing our investment in the Avant Bio, Mission BioCapital and Phoenix Venture Partners funds. His prior investment responsibilities include Adapsyn Bioscience, Arkuda Therapeutics, BioAtla (BCAB), Kymera Therapeutics (KYMR), Mitokinin, Morphic Therapeutic (MORF), and Petra Pharma. Chris brings 25+ years of scientific and corporate leadership, a strong track record of delivering clinical candidates across multiple disease areas and modalities, and proven ability to build and lead highly engaged teams and companies. At Pfizer, he built and led the Applied Synthesis Technologies group within Pfizer R&D to help accelerate the delivery of Pfizer’s small molecule portfolio. Prior to that, Chris built and led Pfizer’s Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in over 10 conjugates entering clinical development. Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates. Chris received his BS in Chemistry from the University of Illinois-Urbana/Champaign and his PhD in Chemistry from the University of Wisconsin-Madison and joined Pfizer after completing post-doctoral studies at the University of California – Irvine.

Northpond Ventures managing director and Scipher Medicine board director, with a background in life sciences investing. Northpond’s current team lists Steve Liapis as Managing Director.

Aizen board member and Madrona investor, independently identified in the issuer’s November2024 financing announcement.

Chris Gibson is the Recursion co-founder and former CEO, joining Dimension in its ownJuly29,2026 announcement. The firm also publicly reposted his direct interview identifying the operating-partner role; he is separately qualified because the current homepage13-person directory does not list operating partners. His existing A-Alpha Bio strategic/scientific adviser and Synteny adviser roles are preserved. A-Alpha’s own individually named portrait verifies the shared identity. An employer role does not infer a personal investment check or end any unrelated adviser appointment.

Managing Partner at KdT Ventures; scientist with experience helping spin out biotechnology companies, joined the firm in2018.

Sara Vaughn, MD, is Chief Medical Officer of Clair Health; her published professional speaker biography describes the role as fractional. She is a physician specializing in obstetrics and gynecology and reproductive endocrinology. Vitra Labs also names her as a clinical advisory board member; that existing separate advisory role is preserved.

Paxton Major serves as Managing Director at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Jefferson Life Sciences strategic adviser and principal of JBW Consulting. Previously served as executive vice president, chief operating officer and chief business officer at Dicerna Pharmaceuticals; also serves on EnPlusOne Bio's board.

Boston senior associate at Polaris since2021, focused on early biotechnology, immunology, oncology, neuroscience and machine-learning therapeutics. Earlier clinical-development experience includes Biohaven Pharmaceuticals.

Polaris managing partner investing in healthcare and early biotechnology. Her current biography confirms Alnylam board chair and Elevance Health director affiliations and her work with QurAlis and other Polaris companies.

Shafique Virani, MD, is a QurAlis director and biotechnology executive. His published biography describes business leadership at Noetik, Recursion, BridgeBio and Genentech, following medical and neurosurgical training in Nottingham, Cambridge and Boston.

Celia Hart is a UroMems board observer and General Partner at Supernova Invest. Her background includes antibody development at Cambridge Antibody Technology and life sciences investing and business development. She holds chemistry and doctoral qualifications from Geneva and Oxford and an MBA from Grenoble École de Management.

Andreas Raabe is published by machineMD as Medical Advisory Board Member. The medical advisory directory associates this external adviser with University Hospital of Bern; advisory service is distinct from company employment.